These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 34619232)

  • 41. The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout.
    Zaqout A; Daghfal J; Alaqad I; Hussein SAN; Aldushain A; Almaslamani MA; Abukhattab M; Omrani AS
    Int J Infect Dis; 2021 Jul; 108():116-118. PubMed ID: 33992763
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neutralizing SARS-CoV-2 antibody response in dialysis patients after the first dose of the BNT162b2 mRNA COVID-19 vaccine: the war is far from being won.
    Torreggiani M; Blanchi S; Fois A; Fessi H; Piccoli GB
    Kidney Int; 2021 Jun; 99(6):1494-1496. PubMed ID: 33887320
    [No Abstract]   [Full Text] [Related]  

  • 43. Immune Response Post-SARS-CoV-2 mRNA Vaccination in Kidney Transplant Recipients Receiving Belatacept.
    Noble J; Langello A; Bouchut W; Lupo J; Lombardo D; Rostaing L
    Transplantation; 2021 Nov; 105(11):e259-e260. PubMed ID: 34387243
    [No Abstract]   [Full Text] [Related]  

  • 44. Clinical Factors Associated With Lack of Serological Response to SARS-CoV-2 Messenger RNA Vaccine in Liver Transplantation Recipients.
    Cholankeril G; Al-Hillan A; Tarlow B; Abrams D; Jacobs JS; Flores NP; Rana A; Kanwal F; Goss JA
    Liver Transpl; 2022 Jan; 28(1):123-126. PubMed ID: 34724328
    [No Abstract]   [Full Text] [Related]  

  • 45. Comparison of BNT162b2 (Pfizer-BioNtech) and mRNA-1273 (Moderna) SARS-CoV-2 mRNA vaccine immunogenicity in dialysis patients.
    Kaiser RA; Haller MC; Apfalter P; Kerschner H; Cejka D
    Kidney Int; 2021 Sep; 100(3):697-698. PubMed ID: 34270945
    [No Abstract]   [Full Text] [Related]  

  • 46. Experience with SARS-CoV-2 BNT162b2 mRNA vaccine in dialysis patients.
    Yanay NB; Freiman S; Shapira M; Wishahi S; Hamze M; Elhaj M; Zaher M; Armaly Z
    Kidney Int; 2021 Jun; 99(6):1496-1498. PubMed ID: 33887318
    [No Abstract]   [Full Text] [Related]  

  • 47. Impact of Shielding and First Dose of COVID-19 Vaccination in Kidney Transplant Recipients.
    Middleton RJ; Gorton J; O'Riordan E; Knight S; Kalra PA; Poulikakos D
    Nephron; 2022; 146(1):64-66. PubMed ID: 34518467
    [No Abstract]   [Full Text] [Related]  

  • 48. A third injection of the BNT162b2 mRNA COVID-19 vaccine in kidney transplant recipients improves the humoral immune response.
    Masset C; Kerleau C; Garandeau C; Ville S; Cantarovich D; Hourmant M; Kervella D; Houzet A; Guillot-Gueguen C; Guihard I; Giral M; Dantal J; Blancho G
    Kidney Int; 2021 Nov; 100(5):1132-1135. PubMed ID: 34474075
    [No Abstract]   [Full Text] [Related]  

  • 49. Waning humoral response 6 months after SARS-CoV-2 vaccination with the mRNA-BNT162b2 vaccine in hemodialysis patients: time for a boost.
    Davidovic T; Schimpf J; Abbassi-Nik A; Stockinger R; Sprenger-Mähr H; Lhotta K; Zitt E
    Kidney Int; 2021 Dec; 100(6):1334-1335. PubMed ID: 34656642
    [No Abstract]   [Full Text] [Related]  

  • 50. Kidney transplant rejection rate in screened patients for anti-SARS-CoV-2 antibodies, during COVID-19 pandemic in Northern Italy.
    Asti AL; Lilleri D; Gregorini M; Zelini P; Pattonieri EF; Sepe V; Libetta C; Islami T; Baldanti F; Rampino T
    New Microbiol; 2021 Jul; 44(3):184-186. PubMed ID: 34783351
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Acute rejection after anti-SARS-CoV-2 mRNA vaccination in a patient who underwent a kidney transplant.
    Del Bello A; Marion O; Delas A; Congy-Jolivet N; Colombat M; Kamar N
    Kidney Int; 2021 Jul; 100(1):238-239. PubMed ID: 33932459
    [No Abstract]   [Full Text] [Related]  

  • 52. Coronavirus Disease 2019 Messenger RNA Vaccine and Liver Transplant Recipients.
    Mungmunpuntipantip R; Wiwanitkit V
    Liver Transpl; 2022 Jan; 28(1):140. PubMed ID: 34506684
    [No Abstract]   [Full Text] [Related]  

  • 53. Concurrent vaccination of kidney transplant recipients and close household cohabitants against COVID-19.
    Perkins GB; Tunbridge M; Salehi T; Chai CS; Kireta S; Johnston J; Penko D; Nitschke J; Yeow AEL; Al-Delfi Z; Drogemuller CJ; Garcia-Valtanen P; Masavuli MG; Hope CM; Singer J; Aggarwal A; Ospina Stella A; Turville SG; Hurtado PR; Barry SC; Hissaria P; Grubor-Bauk B; Chadban SJ; Coates PT
    Kidney Int; 2022 May; 101(5):1077-1080. PubMed ID: 35304094
    [No Abstract]   [Full Text] [Related]  

  • 54. Response to Third Dose of Vaccine Against SARS-CoV-2 in Adolescent and Young Adult Kidney Transplant Recipients.
    Cirillo L; Citera F; Mazzierli T; Becherucci F; Terlizzi V; Lodi L; Buti E; Romagnani P
    Transplantation; 2022 Aug; 106(8):e386-e387. PubMed ID: 35581690
    [No Abstract]   [Full Text] [Related]  

  • 55. The ROMANOV study found impaired humoral and cellular immune responses to SARS-CoV-2 mRNA vaccine in virus-unexposed patients receiving maintenance hemodialysis.
    Espi M; Charmetant X; Barba T; Koppe L; Pelletier C; Kalbacher E; Chalencon E; Mathias V; Ovize A; Cart-Tanneur E; Bouz C; Pellegrina L; Morelon E; Fouque D; Juillard L; Thaunat O
    Kidney Int; 2021 Oct; 100(4):928-936. PubMed ID: 34284044
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunological responses to SARS-CoV-2 vaccines in kidney transplant recipients.
    Prendecki M; Thomson T; Clarke CL; Martin P; Gleeson S; De Aguiar RC; Edwards H; Mortimer P; McIntyre S; Mokreri D; Cox A; Pickard G; Lightstone L; Thomas D; McAdoo SP; Kelleher P; Willicombe M;
    Lancet; 2021 Oct; 398(10310):1482-1484. PubMed ID: 34619100
    [No Abstract]   [Full Text] [Related]  

  • 57. Protecting kidney transplant recipients against SARS-CoV-2 infection: A third dose of vaccine is necessary now.
    Villanego F; Cazorla JM; Vigara LA; Garcia T; Trujillo T; Montiel N; Rodriquez-Iglesias M; Mazuecos A
    Am J Transplant; 2022 Apr; 22(4):1275-1276. PubMed ID: 34467623
    [No Abstract]   [Full Text] [Related]  

  • 58. Successful management of T-cell mediated rejection in a recent kidney transplant recipient with COVID-19 associated severe acute respiratory syndrome.
    Mohamed M; Smith J; Parajuli S; Garg N; Aziz F; Mandelbrot D; Djamali A; Zhong W
    Transpl Infect Dis; 2021 Aug; 23(4):e13598. PubMed ID: 33780103
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 ≥7 days after the 2nd dose.
    Chagla Z
    Ann Intern Med; 2021 Feb; 174(2):JC15. PubMed ID: 33524290
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab.
    Gallo A; Capuano R; Donnarumma G; Bisecco A; Grimaldi E; Conte M; d'Ambrosio A; Coppola N; Galdiero M; Tedeschi G
    Neurol Sci; 2021 Sep; 42(9):3523-3526. PubMed ID: 34128150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.